Charts (c) and (d) may show absolute, not relative, binding.
On rereading, even though the analysis was done using "competitive flow cytometry assay," I think they are saying that, by day 14, virtually 100% of the CCR5 receptors on the bulk T-cells and monocytes were occupied by a molecularly-labeled leronlimab cooked up by BP.
Nowhere for RANTES/CCL5 to attach.
True for every single patient.
Again, help from any doctors out there. I'm not one.